AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth today announced it ranked 238 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. AscellaHealth grew 640% during this three-year period from 2018 to 2021.
AscellaHealth’s president and chief executive officer, Dea Belazi, credits the organization’s tremendous growth with its single-source, end-to-end solutions that tighten the specialty pharmacy (SP) value chain and its focus on optimizing access to expensive specialty and rare disease medications which result in improved patient outcomes. He said, “The AscellaHealth team is honored to share the spotlight with such exceptional companies and we are extremely gratified to earn this distinction. AscellaHealth is proud to offer custom solutions to pharmaceutical manufacturers and other stakeholders that enhance the lives of specialty and rare disease patients throughout the country and globally.”
“As the past year has shown us, innovation in important areas such as life sciences is critical to addressing infectious disease and other global health issues,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In addition, technology must keep pace with ever-changing consumer and corporate demands for faster, safer and more efficient solutions to new societal challenges. Each year I am in awe of the immense talent the Technology Fast 500 rankings reveal, confirming the winners’ relentless pursuit of creativity and their ability to solve real-world problems that benefit us all.”
“This year’s Technology Fast 500 list is a true reflection of some of today’s most determined and inspiring pioneers who have prospered by anticipating what’s next, understanding what’s needed to succeed and driving creativity forward,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit and assurance practice. “Representing all facets of technology, the winners have shown they not only have the vision but can also expertly manage their companies through rapid growth. We congratulate each winner on their impressive achievements.”
AscellaHealth previously ranked 299 as a Technology Fast 500™ award winner for 2021.
Overall, 2022 Technology Fast 500™ companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.
About the 2022 Deloitte Technology Fast 500™
Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About AscellaHealth LLC
AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization serving patients, payers, life sciences manufacturers and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and personalized medical management services. A multiple Inc. 5000 winner and NASP 2022 Strategic Channel Partner of the Year award winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Most recently, AscellaHealth has joined with its subsidiaries, Optime Care and Terebellum to form the AscellaHealth Family of Companies. Visit www.AscellaHealth.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
201.641.1911 x 54
Darcey McDermott, Chief Marketing & Communications Officer
AscellaHealth Family of Companies